Thermo Fisher Scientific (TMO) Other Non-Current Liabilities (2009 - 2026)

Thermo Fisher Scientific has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $4.4 billion for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 11.33% year-over-year to $4.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 billion (up 11.33% YoY) and the FY2025 annual result came in at $4.3 billion, up 7.12% from the prior year.
• Other Non-Current Liabilities improved to $4.4 billion in Q1 2026, from $4.3 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $4.7 billion in Q2 2022 and troughed at $4.0 billion in Q1 2025.
• A 5-year average of $4.3 billion and a median of $4.3 billion in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 39.14% — and 2024, when it fell 14.07%.
• Tracing TMO's Other Non-Current Liabilities over 5 years: stood at $4.2 billion in 2022, then increased by 9.53% to $4.6 billion in 2023, then dropped by 14.07% to $4.0 billion in 2024, then gained by 7.12% to $4.3 billion in 2025, then advanced by 3.46% to $4.4 billion in 2026.
• Business Quant data shows TMO's Other Non-Current Liabilities at $4.4 billion in Q1 2026, $4.3 billion in Q4 2025, and $4.3 billion in Q3 2025.